Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Investing Activities (2022 - 2023)

Spruce Biosciences (SPRB) has disclosed Cash from Investing Activities for 2 consecutive years, with $9.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Cash from Investing Activities fell 36.17% to $9.3 million in Q4 2023 year-over-year; TTM through Sep 2024 was $9.3 million, a 84.77% decrease, with the full-year FY2023 number at $55.8 million, up 135.43% from a year prior.
  • Cash from Investing Activities was $9.3 million for Q4 2023 at Spruce Biosciences, down from $14.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $33.5 million in Q2 2022 to a low of -$16.9 million in Q3 2022.